<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996033</url>
  </required_header>
  <id_info>
    <org_study_id>CV-12-064-GE-HT</org_study_id>
    <nct_id>NCT01996033</nct_id>
  </id_info>
  <brief_title>EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension</brief_title>
  <official_title>This is a Post Market, Multi-center, Open Label, Observational Study. Approximately 500 Subjects With Uncontrolled Hypertension Will Undergo Renal Artery Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to further evaluate the safety and performance of
      the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled
      hypertension in clinical routine practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post market, multi-center, open label, observational study. Approximately 500
      subjects with uncontrolled hypertension will undergo renal artery ablation at approximately
      40 investigational sites located in Germany and will be followed for 1 year post
      procedure.The expected duration of the investigation will be approximately 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean reduction in office Systolic Blood Pressure at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population enrolled in this investigation will consist of males and females
        with uncontrolled hypertension who meet all inclusion criteria, and none of the exclusion
        criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is planned to undergo a renal denervation procedure for the treatment of
             hypertension

          -  Subject is ≥18 years of age at time of consent

          -  Subject must be able and willing to provide written informed consent

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Subject has office Systolic Blood Pressure (SBP) ≥ 140 mmHg

          -  Subject has established hypertension (diagnosed ≥12 months prior to baseline) and is
             on a guideline based drug regimen at a stable (≥ 14 days) and a fully tolerated dose
             consisting of ≥3 anti-hypertensive medications (including 1 diuretic), or subject has
             documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives
             (ACE-I/ Angiotensin Receptor Blocker (ARB), Calcium Channel Blockers, Beta Blockers,
             or diuretic) and is unable to take 3 anti-hypertensive drugs

        Exclusion Criteria:

          -  Subject has known significant renovascular abnormalities such as renal artery
             stenosis &gt; 30%

          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal
             stents, and/or abdominal aortic stent grafts

          -  Subject has a history of hemodynamically significant valvular heart disease

          -  Subject has blood clotting abnormalities

          -  Subject life expectancy is &lt; 12 months, as determined by the Study Investigator

          -  Subject is participating in another clinical study which has the potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph K Naber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elisabeth-Krankenhaus Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kliniken Villingen-Schwenningen</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wurttemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Oberallgäu gGmbH Klinik Immenstadt</name>
      <address>
        <city>Immenstadt</city>
        <state>Bayern</state>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuelklinikum Bernau und Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <state>Brandenburg</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Schwalm-Eder-Kliniken GmbH</name>
      <address>
        <city>Schwalmstadt</city>
        <state>Hesse</state>
        <zip>34613</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universität Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>Northrhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologische Praxis Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <state>Northrhine-Westphalia</state>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Krankenhaus Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40472</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH</name>
      <address>
        <city>Schwäbisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uncontrolled hypertension</keyword>
  <keyword>Renal Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
